U.S. Markets closed

Today’s Research Reports on Canopy Growth, Fennec Pharmaceuticals, Neptune Technologies & Bioressources and TSO3

NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Canopy Growth Corporation
https://rdinvesting.com/news/?ticker=WEED.TO

Fennec Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=FRX.TO

Neptune Technologies & Bioressources Inc.
https://rdinvesting.com/news/?ticker=NEPT.TO

TSO3 Inc.
https://rdinvesting.com/news/?ticker=TOS.TO

Canopy Growth's stock moved 2.91% lower Wednesday, to close the day at $28.74. The stock recorded a trading volume of 4,656,197 shares, which was below its three months average volume of 6,904,769 shares. In the last year, Canopy Growth's shares have traded in a range of 6.58 - 44.00. The share price has gained 336.78% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $32.46 is greater than its 200-day moving average of $19.14. Shares of Canopy Growth have fallen approximately 3.36 percent year-to-date.

Access RDI's Canopy Growth Corporation Research Report at:
https://rdinvesting.com/news/?ticker=WEED.TO

On Wednesday, shares of Fennec Pharmaceuticals recorded a trading volume of 2,488 shares, which was above the three months average volume of 1,370 shares. The stock ended the day 8.28% higher at 12.03. The share price has gained 293.14% from its 52-week low with a 52-week trading range of 3.06 - 16.23. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $11.36 is below its 200-day moving average of $11.73. Shares of Fennec Pharmaceuticals have fallen approximately 3.68 percent year-to-date.

Access RDI's Fennec Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FRX.TO

Neptune Technologies & Bioressources' stock moved 3.46% lower Wednesday, to close the day at $3.63. The stock recorded a trading volume of 84,999 shares, which was below its three months average volume of 314,800 shares. In the last year, Neptune Technologies & Bioressources' shares have traded in a range of 0.86 - 4.41. The share price has gained 322.09% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.86 is greater than its 200-day moving average of $2.05. Shares of the company are trading at a Price to Earnings ratio of 44.27. Shares of Neptune Technologies & Bioressources have gained approximately 22.64 percent year-to-date.

Access RDI's Neptune Technologies & Bioressources Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NEPT.TO

On Wednesday, shares of TSO3 recorded a trading volume of 246,036 shares, which was above the three months average volume of 218,154 shares. The stock ended the day 4.26% lower at 1.35. The stock is currently trading 59.70% below its 52-week high with a 52-week trading range of 1.34 - 3.35. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.06 is below its 200-day moving average of $2.47. Shares of TSO3 have fallen approximately 48.28 percent year-to-date.

Access RDI's TSO3 Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TOS.TO

Our Actionable Research on Canopy Growth Corporation (TSX:WEED.TO), Fennec Pharmaceuticals Inc. (TSX:FRX.TO), Neptune Technologies & Bioressources Inc. (TSX:NEPT.TO) and TSO3 Inc. (TSX:TOS.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com